The graphical representation of the results in Figure 1 of this paper by the Antiretroviral Therapy Cohort Collaboration  was incorrect. The category ‘Drug change within class’ should also be relabelled ‘Substitutions/additions’. The corrected version is reproduced here.
Figure 1. Stacked Cumulative Incidence Functions of class change, substitution/addition of drugs within class, switch to non-standard regimen, interruption and death, estimated using competing risk methods. Figures below the graph are the estimated cumulative incidence of each event at 1, 2 and 3 years, with 95% CIs. *Switches to non-standard regimens included switches to single drugs, dual therapy and regimens containing fusion or integrase inhibitors. Single drugs are mono NRTI, mono NNRTI, mono PI, rarely mono boosted PI (and very rarely mono boosted darunavir). Dual regimens are NRTI + either NRTI, NNRTI or PI.
1. The Antiretroviral Therapy Cohort Collaboration (ART-CC)Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009
© 2014 Lippincott Williams & Wilkins, Inc.